scholarly journals Changes and Prognostic Value of Serum Vascular Endothelial Growth Factor in Patients with Differentiated Thyroid Cancer

2013 ◽  
Vol 22 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Zhen-Hu Zhou ◽  
Xiao-Ning Cui ◽  
Huai-Guang Xing ◽  
Rui-Hong Yan ◽  
Dao-Kuo Yao ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Thyroid Cancer ◽  
Growth Factor ◽  
Prognostic Value ◽  
Differentiated Thyroid Cancer ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Prognostic value of Thymidylate Synthase, Epidermal Growth Factor Receptors and Vascular Endothelial Growth Factor in patients with stage III colon cancer

2006 ◽  
Vol 53 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Dino Tarabar ◽  
Slavica Knezevic-Usaj ◽  
Zoran Petrovic ◽  
Dusan Jovanovic ◽  
Radoje Doder
Keyword(s):  
Colon Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Thymidylate Synthase ◽  
Prognostic Value ◽  
Epidermal Growth Factor Receptors ◽  
Vascular Endothelial ◽  
Epidermal Growth ◽  
Endothelial Growth Factor ◽  
Dukes C

Purpose: We studied the prognostic value of thymidylate synthase (TS), Epidermal Growth Factor Receptors (EGFR) and Vascular Endothelial Growth Factor (VEGF) expression in primary colon cancer (CC). Patients and Methods : Those three markers were immunohistochemically assessed on tumor sections from 100 patients with CC Dukes C. All patients received the same adjuvant chemotherapy with FU/Leukovocin according to Mayo protocol. Considering the clinical course they were classified in two groups: bad in which all patients progressed and good in which neither progressed during the five year follow up period. Results: TS, EGFR and VEGF were an independent prognostic factor for time to progression (TTP) and overall survival (OS). Findings of at least two maximum expressed investigated markers, significantly increases the risk of progression which influences shorter five year survival, and the single maximum expression does not necessarily have to be a bad prognostic sign. Conclusion: Highest expression of TS, EGFR and VEGF carries prognostic significance with respect to TTP and OS for patients with Dukes C colon cancer.

scholarly journals Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

2017 ◽  
Vol 5 (2) ◽  
pp. 167-172 ◽  
Author(s):  
Fahredin Veselaj ◽  
Suzana Manxhuka-Kerliu ◽  
Arber Neziri ◽  
Labinot Shahini ◽  
Shefki Xharra ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cell ◽  
Prognostic Value ◽  
Clear Cell ◽  
Vascular Endothelial ◽  
Cell Renal Cell Carcinoma ◽  
Free Survival ◽  
Endothelial Growth Factor

BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.MATERIAL AND METHODS: Tumour blocks were taken from 40 patients with histopathology diagnosis of CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-histochemical staining for VEGF-A.RESULTS: The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (U’ = 720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific Survival   (r = -0.207, P = 0.713).CONCLUSIONS: VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for VEGF-A expression in all patients with advanced and metastatic CCRCC.

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.

1998 ◽  
Vol 16 (9) ◽  
pp. 3121-3128 ◽  
Author(s):  
B Linderholm ◽  
B Tavelin ◽  
K Grankvist ◽  
R Henriksson
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Overall Survival ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Systemic Therapy ◽  
Prognostic Value ◽  
Vascular Endothelial ◽  
Node Negative ◽  
Endothelial Growth Factor ◽  
Vegf Level

PURPOSE The prognostic value of vascular endothelial growth factor (VEGF) protein, known to stimulate endothelial growth and angiogenesis, was evaluated in node-negative breast carcinoma (NNBC) and compared with established prognostic factors. PATIENTS AND METHODS In 525 consecutive patients with primary invasive NNBC (T1-2N0M0; tumor, node, metastasis stage), of whom 500 patients did not receive any systemic therapy, the cytosolic levels of VEGF165 were measured by using a quantitative enzyme-linked immunosorbent assay. The median follow-up was 46 months. Univariate and multivariate analyses were performed. RESULTS VEGF level was significantly inversely correlated with estrogen receptor (ER) positivity but positively associated with tumor size and histologic grade. Patients with VEGF levels above the median value (2.40 pg/microg of DNA) showed a significantly shorter survival time (P=.0012) than patients with levels less than the median value, also when analyzed as a continuous variable (P=.0277). Tumor size, grade, and ER expression were all statistically significant for overall survival in univariate analyses (P=.0069, P=.014, and P < .001, respectively). Multivariate analysis showed that VEGF level was the strongest predictor of overall survival (P=.0199). Histologic grade was also an independent predictor of survival (P=.0477). Among the 381 patients with ER-positive tumors, a group in general considered to have a good prognosis, we found a significant reduction in survival for those with levels of VEGF greater than the median value (P=.0009). CONCLUSION The results suggest that the level of VEGF165 protein is an independent, strong prognostic factor for survival in patients with NNBC, especially in the subgroup of patients with ER positivity. Thus, cytosolic VEGF165 might be useful to select patients for adjuvant systemic therapy.

scholarly journals The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter

2007 ◽  
Vol 157 (4) ◽  
pp. 521-527 ◽  
Author(s):  
Joanna Klubo-Gwiezdzinska ◽  
Roman Junik ◽  
Ewa Kopczynska ◽  
Olga Juraniec ◽  
Hanna Kardymowicz
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Thyroid Cancer ◽  
Growth Factor ◽  
Healthy Subjects ◽  
Multinodular Goiter ◽  
Distant Metastases ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Tsh Stimulation ◽  
Metastatic Thyroid Cancer

Background: One of the important proangiogenic factors involved in the growth of normal and neoplastic tissues is vascular endothelial growth factor (VEGF). Aim: We hypothesized that serum VEGF concentration would differ between patients with metastatic and non-metastatic thyroid cancer, multinodular goiter, and healthy subjects. We also hypothesized that endogenous TSH stimulation would affect serum VEGF level. Subjects and methods: The study group consisted of 71 patients (62 females and 9 males), aged 44.9 ± 12.3 years, with differentiated thyroid cancer (50 papillary, 17 follicular, and 4 oxyphilic), treated in our department during the years 2003–2006. All patients had undergone total or near-total thyroidectomy and radioactive iodine treatment, that had resulted in remission in 59 patients and persistent/recurrent disease in 12 patients. The study included two control groups: 30 patients with nontoxic multinodular goiter and 30 healthy subjects. Results: Serum VEGF concentrations were significantly higher in patients with distant metastases than those in remission or healthy patients. (423.4 vs 217.6 vs 235.55 pg/ml respectively, P < 0.05). This was not observed in patients with locoregional metastases. During endogenous TSH stimulation, VEGF decreased significantly (215.3 vs 169.6 pg/ml, P < 0.05). Patients with multinodular goiter showed significantly lower VEGF concentrations than the remaining study groups. Conclusions: Serum VEGF concentration might be used as an additional marker of thyroid cancer with distant metastases, but its interpretation should be undertaken very cautiously. Endogenous TSH stimulation decreases VEGF levels in patients either with or without thyroid tissue, suggesting that its regulatory effects are through receptors located outside the thyrocytes.

scholarly journals Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors

2015 ◽  
Vol 33 (5) ◽  
pp. 2345-2353 ◽  
Author(s):  
MARINA GOBBE MOSCHETTA ◽  
LARISSA BAZELA MASCHIO ◽  
BRUNA VICTORASSO JARDIM-PERASSI ◽  
GABRIELA BOTTARO GELALETI ◽  
JULIANA RAMOS LOPES ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Value ◽  
Hypoxia Inducible Factor ◽  
Mammary Tumors ◽  
Vascular Endothelial ◽  
Hypoxia Inducible Factor 1Α ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document